GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml

Product Details
Customization: Available
Quality Standard: Bp, USP
Ctd Dossier: Ready
Still deciding? Get samples of US$ 0.01/Piece
Request Sample
Manufacturer/Factory, Trading Company, Group Corporation
Gold Member Since 2018

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Importers and Exporters
The supplier has import and export rights
to see all verified strength labels (7)
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
  • GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
Find Similar Products

Basic Info.

Model NO.
injection
Documentation
Copp, COA
Factory Certification
GMP
Transport Package
Carton
Specification
100ml
Trademark
Sinolead
Origin
China
Production Capacity
100, 000, 000 Per Year

Product Description

 
Generic Name Ciprofloxacin Lactate and Sodium Chloride Injection
Strength 100ml 
Packing 1 bottle / box
Origin China

Value-added services:
 Packaging design by our team
 
Registration service by our team

 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------


Product name:
Ciprofloxacin Lactate and Sodium Chloride Injection 100ml

Character:
This product is colorless or almost colorless clear liquid.

Indications:
For simple and complex infections caused by ciprofloxacin-sensitive pathogens. When intravenous administration is beneficial to the patient:
Urinary tract infections - mild, moderate, severe and concurrent infections, applicable to the following pathogens: Escherichia coli (including secondary bacteremia), Klebsiella pneumoniae subspecies pneumonia, Enterobacter clovis, Serratia marcescens, Proteus mirabilis, Pluffetenella reggii. Morgan Bacillus, citrobacter Divos, citrobacter Fraudiensis, Pseudomonas aeruginosa, Staphylococcus epidermidis or Enterobacter faecalis.
Lower respiratory tract infection - Mild to moderate infection for the following causes: E. coli, Klebsiella pneumoniae subspecies pneumonia, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae and Haemophilus parainfluenza, and Streptococcus pneumoniae.
Skin and soft tissue infections - Mild to moderate infections for the following causes: Escherichia coli, Klebsiella pneumoniae subspecies pneumonia, Enterobacter cloacae, Proteus Mirabilis, Proteus vulgaris, Pruffeella stuartii, Bacillus morgana, Citrobacter Fredii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes.
Bone and joint infections - mild to moderate infections, suitable for infections caused by Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa.
If the infection may be caused by anaerobic bacteria, appropriate treatment should be taken.
In order to isolate and identify the bacteria causing the infection and determine their sensitivity to Siproxacin ®, appropriate bacterial cultures and susceptibility tests should be performed. The results of these trials may be treated with Siproxacin ® by intravenous drip until the results are reported, and the most appropriate treatment should be used once the results are clear.
Similar to other drugs, some strains of P. aeruginosa can rapidly develop resistance when treated with Siproxacin ®, so regular bacterial culture and susceptibility testing during treatment can not only understand the antibacterial effect, but also obtain information about the potential for resistance.
Inhalation anthrax in adults and children (post-exposure) : Reduces the incidence of disease after inhalation of atomized anthrax bacilli and delays disease progression.

Taboo: 
Contraindicated in patients allergic to ciprofloxacin, other quinolone chemicals, or any excipients thereof.
It should not be used in children or adolescents, because there is no safety experience in these patients, and based on animal studies, it cannot be completely ruled out that this drug causes articular cartilage damage in immature organs.
The combination of ciprofloxacin and tizanidine increases the concentration of Tizanidine in blood, leading to associated clinical adverse reactions (such as hypotension, drowsiness, and drowsiness), so the contraindicated use of ciprofloxacin and tizanidine is recommended.


Storage:
Ciprofloxacin is sensitive to light and should be used immediately after the injection bottle is removed from the box. Under light conditions, the undiluted solution remained fully effective for 3 days.
The solution will precipitate when stored at low temperature, and will disappear when restored to normal temperature. Therefore, storage in the refrigerator is not recommended.
Keep medicines out of reach of children.
Do not use after the expiration date.

 

GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml 
 

GMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100mlGMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100mlGMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100mlGMP Certified / Ciprofloxacin Lactate and Sodium Chloride Injection 100ml
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier